Frequency Of HLA-B Research Articles

Prevalence of HLA-B27 in Moroccan healthy subjects and patients with ankylosing spondylitis and mapping construction of several factors influencing AS diagnosis by using multiple correspondence analysis.

The aim of the present study was to determine the prevalence of human leukocyte antigen HLA-B27 in Moroccan healthy controls and in patients with ankylosing spondylitis (AS), and to analyze the correlation between HLA-B27 and AS in Moroccan patients. The prevalence of HLA-B27 was determined by evaluating the number of HLA-B27-positive samples in 128 healthy subjects and in 53 patients diagnosed with AS according to the ESSG and AMOR criteria. HLA-B27 was determined by the polymerase chain reaction using sequence-specific primers. Multivariate analysis of our data (HLA-B27, age, sex, and family history) for AS and healthy controls was performed by multiple correspondence analysis (MCA). The frequency of HLA-B27 was significantly greater in AS patients (45.3 %) than in healthy controls (4.7 %) [p < 0.0001, OR 16.8, and CI 95 % (5.83-51.03)]. In addition, HLA-B27 was more common in male patients than in female ones (p < 0.05). 100 % of the AS patients reported a family history of AS, whereas only 20 % of the healthy controls reported a family history of AS. The graphical interpretation of MCA showed a significant relation between the presence of HLA-B27 and AS. This study strengthens the link between HLA-B27 and AS and represents a very valuable informative diagnostic tool, especially in regard to male patients who have a family history of AS.

A comparison of clinical and laboratory profile of non-radiographic axial spondyloarthritis and ankylosing spondylitis

ObjectivesTo investigate the differences in clinical presentation, disease activity, HLA-B27 positivity in nr-axSpA and AS. MethodsProspective observational study conducted in tertiary care centre from India. Total 125 consecutive patients with chronic low backache were screened,96 fulfilling ASAS criteria for axial SpA were included and grouped into radiographic (AS) (n = 55) and non-radiographic (n = 41) axial SpA. Demographic, clinical, disease activity and functional indices, ESR were noted from study group. HLA B27 testing was performed in study group by using an in-house PCR method. ResultsPatients with AS compared with nr-axSpA were older at presentation (mean 33.7 ± 11.9 vs 26.5 ± 9, p < 0.001), longer mean time to disease diagnosis (4.4 ± 4 vs 1.3 ± 1.7,p < 0.0001) and had higher proportion of positive family history of SpA(29% vs 9.7%,p = 0.02). No statistical significant differences were found in male to female ratio, peripheral arthritis, dactylitis, enthesitis, ESR, HLA B27 positivity, disease activity and functional indices (BASDAI,BAS-G&BASFI) ConclusionThough the clinical features and HLA B27 frequency is similar in nr-axSpA and AS, Patients with AS were older and had longer disease duration.

A Survey on the Frequency of HLA-B27 in Patients Engaged With Seronegative Spondyloarthropathies in Kashan, Iran

Background: Seronegative Spondyloarthropathies (SNSAs) are referred to a group of diseases with same clinical and genetic features. Objectives: Due to lack of data about HLA-B27 prevalence in patient with SNSA in Kashan this study was conducted to determine the status of HLA-B27 in these patients. Patients and Methods: This cross sectional study was conducted on 294 patients suffered from SNSA. Presence or absence of HLA-B27 was checked by serological method using Greener kit. Results were analyzed with SPSS-16 software using t-test and χ 2 test. Results: Of all 26.5% of subjects were HLA-B27 positive. HLA-B27 was significantly more frequent in male patients (34.1% vs. 16.5%, P < 0.001). Prevalence of HLA-B27 was 69% in ankylosing spondylitis, 31.5% in psoriatic arthritis, 18.2% in entropathic arthropathy, 17.9% in undifferentiated spondyloarthropathies, 16.1% in reactive arthritis and 12.5% in juvenile rheumatoid arthritis (P < 0.001). Conclusions: HLA-B27 has highest prevalence in ankylosing spondylitis and least prevalence in juvenile rheumatoid arthritis. HLA-B27 prevalence was in relation with gender, type of disease, family history, peripheral, and axial joints engagement.

HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese.

Methazolamide is an intraocular pressure-lowering drug that is used in the treatment of glaucoma and other ophthalmologic abnormalities. The use of methazolamide has been shown to cause Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients of Asian ancestry. Methazolamide-induced SJS/TEN is associated with the presence of HLA-B59 serotype/HLA-B*59:01 in Korean and Japanese populations. To better understand the genetic risk factors for these adverse reactions in the Han Chinese population, we characterized the HLA class I genotypes of eight Chinese patients with methazolamide-induced SJS/TEN from 2008 to 2014. The frequency of HLA-B*59:01 was 87.5% (7/8) in the case patients, which was significantly different from 0% (0/30) in the methazolamide-tolerant patients (odds ratio (OR)=305.0; P=6.3 × 10(-7)) and 0.35% (1/283) in healthy subjects from the human major histocompatibility complex database (OR=1974.0; P=2.0 × 10(-12)). HLA-C*01:02, which is closely linked to HLA-B*59:01, had a weaker but notable association with methazolamide-induced SJS/TEN compared with the tolerant controls (OR=12.1; P=0.016) and general population (OR=15.5; P=2.0 × 10(-3)). The distribution of the HLA-B*59:01-C*01:02 haplotype was also significantly different in cases and controls. This study demonstrated a strong association between HLA-B*59:01 and methazolamide-induced SJS/TEN in the Han Chinese population for the first time. Pretherapy screening for HLA-B*59:01 would be useful to reduce the risk of methazolamide-induced SJS/TEN.

Rapid human immunodeficiency virus disease progression is associated with human leukocyte antigen-B homozygocity and human leukocyte antigen-B51 in a cohort from Manitoba, Canada

Background: Human immunodeficiency virus type 1 (HIV-1) infection is associated with variable rates of disease progression, influenced by the quality of CD8 T-lymphocyte response, which is determined by human leukocyte antigen (HLA) I alleles. Some individuals progress slowly and maintain viral control, while at the opposite end of the spectrum some individuals endure a faster progression with rapid CD4 decline. We sought to determine the role of HLA-B allele frequency on rapid HIV disease progression. It was hypothesized that rapid progression is associated with the presence of high allele frequency of HLA-B35 and HLA-B homozygocity. Methods: This retrospective cohort study was conducted in the Manitoba HIV Program, Health Sciences Centre, a tertiary care facility in Winnipeg, Manitoba, Canada. We defined a set of new criteria to describe a subset of individuals with the most rapid HIV disease progression, and collected demographic, clinical, laboratory (CD4 count, viral load) and HLA data on a subset of 20 individuals meeting these criteria. Results: Among those individuals who display extreme rapid progression, an overrepresentation of Aboriginal ethnicities, high frequencies of HLA-B35 and significantly higher rates of HLA-B51, as well as a very high rate of homozygocity for HLA-B alleles, were observed. Conclusions: Individuals with the most rapid disease progression have higher rates of HLA-B homozygocity, HLA-B51 alleles and higher viral loads than those with normal progression rates. This group, at the extreme end of the spectrum of progression, should be targeted for early treatment.

Antibiotic Allergies in a Birth Cohort from 2007

S U N D A Y 370 The Association of HLA-B* 5101 and Phenobarbital-Induced Severe Cutaneous Adverse Drug Reactions in Thai Children Plernpit Likkasittipan, MD, Wiparat Manuyakorn, MD, Surakameth Mahasirimongkol, Suwat Benjaponpitak, MD, Anannit Visudtibhan, Nuanjun Wichukchinda, Sukanya Wattanapokayakit; Division of Pediatric Allergy/Immunology/Rheumatology, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand, Division of Pediatric Allergy/Immunology/Rheumatology, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Medical genetic center, Medical Life Science Institute, Department of Medical Science, Ministry of Public Health, Nonthaburi, Thailand, Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand. RATIONALE: Adverse drug reactions to phenobarbital (PB), the firstline aromatic anticonvulsant drug, are maculopapular rash (MP) and severe cutaneous adverse drug reactions (SCARs) including drug rash with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These conditions have highmortality rate and are usually unpredictable. This preliminary study aims to investigate the association between variations of HLA genotypes and phenobarbitalinduced SCARs among Thai children. METHODS: Thai children aged between 0-18 years who were diagnosed with phenobarbital hypersensitivity from 2004-2014. Control patients were phenobarbital-tolerant Thai children with corresponding age groups. Their HLA-B locus was genotyped using a PCR technique. RESULTS: A total of 45 Thai children were enrolled. Thirteen children were diagnosed with phenobarbital hypersensitivity (7 with MP and 6 with SCARs). Thirty two phenobarbital-tolerant children were recruited as control. The frequency of HLA-B*5101 in phenobarbital-induced SCARs was 50% (3/6) while only 6% (2/32) was found in the drug-tolerant children (OR515, 95%CI (1.75-128) p5 0.02). No patient with phenobarbital-induced MP was found to carry HLA-B*5101. The frequency of HLA-B*1502 in phenobarbital-induced MP was 14.3%, phenobarbitalinduced SCARs was 16.7% and drug tolerant was 12.5%. We did not find any association between phenobarbital-induced MP and SCARs and HLA-B*1502, a known HLA genotype associated with anticonvulsant hypersensitivity in previous study. CONCLUSIONS: Our preliminary study shows an association between HLA-B*5101 and phenobarbital-induced SCARsamong Thai children.

The frequency of HLA-B∗57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica

HLA-B∗57:01 is a well-known and cost-effective pharmacogenetic marker for abacavir hypersensitivity. As with other HLA alleles, there is widespread variation in its frequency across populations. The Costa Rica Central Valley Population (CCVP) is the major population in this country. The frequency of HLA-B∗57:01 in this population has not been described yet. Thus, our aim was to determine the frequency of this allele in the CCVP. 200 unrelated healthy volunteer donors born in the CCVP were typed. HLA-B∗57-positive samples identified by HLA intermediate resolution typing methods were further typed by SBT to high resolution. An HLA-B∗57:01 carrier frequency of 5.00% was determined in this sample. This frequency is relatively high in comparison to reports from other populations in Latin America. These results suggest that there is a considerable frequency of HLA-B∗57:01 in the CCVP and that pharmacogenetic testing for HIV+ patients who are going to receive abacavir-based treatment should be considered in this country.

P111 : DISTRIBUTION OF CLASS I AND II HLA HAPLOTYPES IN A MIXED POPULATION FROM SOUTHERN BRAZIL

The aim of this study was evaluate of allele and haplotype frequencies of HLA-A, -B, -DRB1, -DQA1 and -DQB1 in a mixed population from Southern Brazil. Sample donors registered in the National Registry of Bone Marrow Donors (REDOME) were analyzed. Four hundred and seventy-three (67%) subjects were female while 231 (33%) were male. The average age was 33.63 years (SD = 9.37). Genotyping allelic groups of HLA-A , -B-DQA1 and DQB1 was performed by PCR-SSO with Luminex method (One Lambda®, CA, USA) and the HLA-DRB1 alleles was performed by PCR-SSOP HD (High Definition) methodology with Luminex (One Lambda®, CA , USA) in 704 individuals. The distribution of HLA alleles was in Hardy-Weinberg equilibrium. Twenty-two allelic groups were observed for HLA-A locus, the most frequent HLA-A ∗ 02 (27.1%), ∗ 03 (10.7%), ∗ 24 (9.6%), ∗ 01 (9.5%), ∗ 68 (6.3%) and ∗ 11 (5.4%), while for HLA-B locus with 34 allelic groups were the most frequent HLA-B ∗ 35 (12.1 %), ∗ 44 (10.2%), ∗ 51 (8.5%), ∗ 15 (7.5%), ∗ 7 (7.3%) and ∗ 18 (6.5%). The most common DRB1 alleles were: HLA-DRB1 ∗ 07:01 (13.2%), ∗ 03:01 (9.1%), ∗ 11:01 (8.4%), ∗ 15:01 (6.1%) ∗ 1:01 (5.92%) and ∗ 13:01 (5.9%). For the loci HLA-DQA1 and HLA-DQB1: HLA-DQA1 ∗ 01:02 (16.8%), ∗ 05:05 (15.8%) ∗ 02:01 (13.1%), 05:01 (9.8%), ∗ 01:01/04/05 (9.1%); HLA-DQB1 ∗ 03:01 (20.1%), ∗ 05:01 (14.1%), ∗ 02:02 (11.9%), ∗ 02:01 and ∗ 03:02 (9.74%). Four hundred HLA-A/B found possible haplotype, with HLA-A ∗ 02/B ∗ 51 (4.3%), A ∗ 02/B ∗ 15 (2.9%) and A ∗ 01/B ∗ 08 (2.9%) were the most frequent. We observed 2839 HLA-A/B/DRB1 possible haplotypes and the most common were HLA-A ∗ 01/B ∗ 08/DRB1 ∗ 03:01 (2.7%) and A ∗ 29/B ∗ 44/DRB1 ∗ 07:01 (1.9%). For HLA-DRB1/DQA1/DQB1 observed in 1369 possible haplotypes, the most frequent were HLA-DRB1 ∗ 03:01/DQA1 ∗ 05:01/DQB1 ∗ 02:01 (8.4%) and HLA-DRB1 ∗ 11:01/DQA1 ∗ 05:05/DQB1 ∗ 03:01 (5.7%), and the HLA-DQA1 ∗ 05:05/DQB1 ∗ 03:01 (14.9%) and HLA-DQA1 ∗ 02:01/DQB1 ∗ 02:02 (10.9%) were the most frequent. The results obtained for the haplotype extended HLA-A/B/DRB1/DQA1/DQB1 is given below: 15,006 possible haplotypes and HLA-A ∗ 01/B ∗ 08/DRB1 ∗ 03:01/DQA1 ∗ 05:01/DQB1 ∗ 02:01 (2.7%); HLA-A ∗ 29/B ∗ 44/DRB1 ∗ 07:01/DQA1 ∗ 02:01/DQB1 ∗ 02:02 (1.8%), the most frequent haplotypes.

Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR.

The HLA-B*58:01 allele is associated with allopurinol-induced severe cutaneous adverse drug reactions (sCADR) in certain geographic regions, but the diversity of the correlation is large. In addition, the currently available HLA-B*58:01 testing methods are too laborious for use in routine clinical detection. The objective of this study was to develop a new, convenient method for the detection of HLA-B*58:01 and to investigate the association of HLA-B*58:01 with allopurinol-induced sCADR in a Han Chinese population. A new method combining sequence-specific primers (SSP) and TaqMan probe amplification was developed in this study and was used to detect the HLA-B*58:01 in 48 allopurinol-induced sCADR, 133 allopurinol-tolerant, and 280 healthy individuals. The accuracy, sensitivity, and specificity were assessed by a commercial PCR-SSP HLA-B typing kit. The low limit of detection was detected by serial dilution of an HLA-B*58:01-positive DNA template. The new method successfully identified HLA-B*58:01 in thousands of HLA-B alleles, and the results for 344 DNA samples were perfectly concordant with the results of the commercial PCR-SSP HLA-B kit. The analytical sensitivity is 100% and the specificity is over 99%. The low limit of detection of this assay is 100 pg DNA, which was 10 times more sensitive than the commercial PCR-SSP kit. HLA-B*58:01 was present in 93.8% of the patients with sCADR, 7.5% of the allopurinol-tolerant patients, and 12.1% of the healthy controls. The frequency of HLA-B*58:01 was significantly higher in the sCADR group than in the control group (p<0.0001). However, there was no significant difference between the allopurinol-tolerant and control groups (p=0.1547). HLA-B*58:01 has a strong association with allopurinol-induced sCADR in Han Chinese. The newly developed method is reliable for HLA-B*58:01 detection prior to allopurinol therapy.

Association between HLA‐B*1502 allele and aromatic antiepileptic drugs‐induced hypersensitivity syndrome reactions and the HLA‐B*15:02 pharmacogenetics screening in autistic spectrum disorder

Some autistic children also have symptoms of depression, anxiety or obsessive-compulsive disorder (OCD). Aromatic anti-epileptic drugs (AEDs) may be used as a mood-stabilizing medication to treat these symptoms, including carbamazepine (CBZ), oxcarbazepine (OX-CBZ), and lamotrigene (LMG). Moreover, one in every four autistic spectrum disorder children have seizures, the use of AED becomes imperative in managing symptoms. Previous studies found a strong association between HLA-B*1502 and carbamazepine (CBZ)-induced cutaneous adverse reactions in Thai epileptic patients. This study aimed to identify whether HLA-B*1502 is associated with AEDs-induced hypersensitivity syndrome (HSS) reactions and also determine the frequency of HLA-B*15:02 in autistic spectrum disorder (ASD) in Thailand. In this study, patients that developed fever and cutaneous eruptions in the presence or absence of organ involvement with exposure to carbamazepine (CBZ), phenytoin (PHY), or lamotrigine (LTG) were enrolled. HLA-B* 15:02 was then determined in 21 patients with AED-induced HSS (6 with CBZ-HSS, 4 PHY-HSS patients and 11 LTG-HSS patients and 292 children with ASD. HLA-B genotyping using PCR-SSOP methods was performed. HLA-B*15:02 was observed with HSS-induced by AEDs, which included carbamazepine (n=4; 66.7%), phenytoin (n=2; 50%), and lamotrigine (n=3; 27%). In addition, the allele frequencies of HLA-B*15:02 in ASD was 14.72% (43/292). HSS-induced by CBZ, PHY and LMG is strongly, moderately and slightly associated with HLA-B*15:02 in Thai patients, respectively. Our findings suggest that HLA-B*15:02 testing before AED therapy would be effective at risk of hypersensitivity and applicable to ASD populations providing hope for prevention in the future.

Associations between polymorphisms of HLA-B gene and postmenopausal osteoporosis in Chinese Han population.

Osteoporosis is a systemic skeletal disease, which is more prevalent in postmenopausal women. Osteoporosis likely develops beginning with genetic risk. This study explored the relationships between polymorphisms of HLA-B gene and postmenopausal osteoporosis in a Chinese Han population. Polymerase chain reaction sequence-based typing (PCR-SBT) method was used for DNA typing at HLA-B locus in 70 patients with postmenopausal osteoporosis and 73 healthy controls in female Han population of Shaanxi Province, situated in north-western China. We found that 40 HLA-B alleles in postmenopausal osteoporosis patients and control subjects, respectively. Furthermore, the frequency of HLA-B* 3501 allele was significantly higher in postmenopausal osteoporosis patients than in the control group (P = 0.033), and the relative risk was 7.632 (95% CI: 0.927-62.850). Our results suggest that HLA-B* 3501 was likely an important risk factor for postmenopausal osteoporosis. As different populations have different HLA polymorphisms, further investigation of the relationship of various HLA genes and osteoporosis with larger sample size is still necessary in the future.

AB0754 Psoriatic Arthritis (PSA): an Indian Perspective

BackgroundPsoriatic arthritis is a major rheumatological problem. The heterogenous phenotype spectrum spans from RA like to a typical AS. There are few descriptions from IndiaObjectivesTo evaluate the clinical phenotype &...

FRI0130 Clinical and Imaging Differences between Patients with Familial Early Axial Spondiloarthritis and Sporadic Forms: Results from Esperanza Cohort

BackgroundAt present, there are few studies on how genetic factors may influence phenotypic expression in familial and sporadic early axial spondyloarthritis (axSpA). To help physicians better understand SpA, our group...

An update on the contribution of the MHC to AS susceptibility.

The 40-year-old association of HLA-B27 with ankylosing spondylitis is one of the best examples of disease association with a hereditary marker. Genomewide association and family studies suggest that other important major histocompatibility complex (MHC) influences are operative in ankylosing spondylitis (AS) susceptibility. HLA-B27 positive hepatitis C individuals are immunologically more efficient in combating viral infections such as HIV-1, hepatitis C, and influenza and less efficient in combating against certain bacteria (and perhaps other organisms) capable of surviving intracellularly. A recent representative population survey of the frequency of HLA-B27 in the USA found a lower frequency of HLA-B27 in older US adults, perhaps reflecting this. Other HLA class I and class II alleles have been implicated in AS susceptibility, the most consistent being HLA-B*40/B60 (B*40:01) but also B14, B15, A*0201, DRB1*04:04, and certain DPA1 and DPB1 alleles. Non-HLA MHC alleles have also been implicated, although many such studies have been inconsistent, likely due to power issues related to the low number of HLA-B27-negative AS patients examined. The best evidence is for major histocompatibility complex class I chain-related gene A (MICA) whose recognition by intestinal epithelial T cells expressing different V-delta-1 gamma/delta TCR further implicates the gut in AS pathogenesis. The HLA class I and class II and other non-HLA allelic associations underscore the importance of T cells in AS pathogenesis.

Associations of HLA gene with leukemia in 1186 cases

The purpose of this study was to evaluate the potential associations between HLA-A, B, DRB1 gene and leukemia. A total of 1186 leukemic patients, including 326 patients with acute lymphoblastic leukemia (ALL), 545 patients with acute myeloid leukemia (AML), 315 patients with chronic myeloid leukemia (CML), and 1234 healthy unrelated donors were typed and were compared in a single centre by using same technique, then the Bonferroni correction method was used to correct the Type I error. The results indicated that as compared with the control,the frequency of HLA-DRB1(*)09 in ALL group significantly decreased (10.87% versus 16.08%; Pc = 0.014, OR = 0.637, 95% CI = 0.487-0.834), while in comparison with control, the frequency of HLA-B(*)18 in CML group was significantly higher (1.28% vs 0.20%; Pc = 0.039, OR = 6.336, 95% CI = 2.066-19.434). The positive and negative relation may exist between certain HLA molecules and leukemia. The negative relation between HLA-DRB1(*)09 and ALL indicated that DRB1*09 might play an important role by a restricted T-cell immune response in the early leukemogenic events, whereas the positive relation between HLA-B(*)18 and CML suggests that the B(*)18 molecules may not actively present leukemia-specific antigens resulting in immune escape. It is concluded that these findings can contribute to developing more appropriate method in leukemic immunotherapy.

HLA-B27 Allele Frequency in a Turkish Study Population with Primary Osteoarthritis

Abstract Aim: It was aimed to determine the frequency of HLA-B27 allele in patients with primary osteoarthritis in a Turkish study population. Materials and Methods: Genomic DNA was extracted from 87 patients with primary osteoarthritis and 51 healthy controls in the study. DNA was amplified by using HLA-B27 PCR kit. Products were assessed with UV transluminator by being exposed to 2% agarose gel electrophoresis. Results: There was no significant difference between patients and controls. Frequency of HLA-B27 was %16 in patients and %19 in control group. Conclusion: This study gives an idea about the frequency of HLA-B27 in primary osteoarthritis. We may assert that the frequency of HLA-B27 in primary osteoarthritis does not differ from the healthy population.

Application of a Simple In-House PCR-SSP Technique for HLA-B* 27 Typing in Spondyloarthritis Patients

Background. Microlymphocytotoxicity (MLCT) and flowcytometry (FC) are the conventional serological methods to detect HLA-B* 27. Due to some disadvantages in these methods, most of the HLA laboratories have now switched over to molecular methods. Molecular techniques based on commercial kits are expensive; as such many laboratories with limited funds in developing countries cannot afford these techniques. Aims. Our main aim was to standardize a simple inexpensive in-house PCR-SSP technique for HLA-B* 27 typing. Materials and Methods. Sequence Specific primers were designed to amplify all the subtypes of B* 27 using IMGT-HLA sequence database. Accuracy was checked by retyping of 90 PCR-SSOP typed controls. Results. The presence of 149 bp specific band with control band on 2% agarose gel showed B* 27 positivity. No discrepancies were found when compared with PCR-SSOP results. The frequency of HLA-B* 27 was found to be significantly increased (68.75% versus 4.40%, O.R 46.909: P value 6.62E − 32) among 700 SpA patients as compared to controls. Clinically, 54% of patients had polyarticular arthritis with SI joints involvement (68%) and restricted spine flexion (60%). Conclusion. In-house PCR-SSP technique is very simple and inexpensive technique to detect B* 27 allele, which was strongly associated with SpA patients from Western India.

HLA-B50 polymorphism in the Saudi population

The HLA-B50 serologic family is very frequent in people of Arabic origin. In Saudi Arabia, HLA-B50 is the most frequent HLA-B allele. The aim of this study was to investigate the distribution of HLA-B50 alleles in healthy Saudi individuals. A total of 162 healthy Saudi individuals were selected based on low-resolution HLA typing. DNA samples were typed by sequence-based typing method for exons 2, 3 and 4 of the HLA-B locus (Genome Diagnostics B.V.). The HLA-B*50 alleles were analysed using SBT engine software. HLA-B*50:01:01 was found in 161 of 162 individuals (99.4%), while HLA-B*50:09 was found in one individual (0.6%). HLA-B*50:01:01 is the most common HLA-B50 allele in Saudi Arabia.

Enteropathic arthritis in Brazil: data from the Brazilian registry of spondyloarthritis

Inflammatory bowel diseases (Crohn's disease and ulcerative rectocolitis) have extraint- estinal manifestations 25% of the patients, with the most common one being the entero- pathic arthritis. MethodsProspective, observational, multicenter study with patients from 29 reference cen- ters participating in the Brazilian Registry of Spondyloarthritis (RBE), which incorporates the RESPONDIA (Ibero-American Registry of Spondyloarthritis) group. Demographic and clinical data were collected from 1472 patients and standardized questionnaires for the as- sessment of axial mobility, quality of life, enthesitic involvement, disease activity and func- tional capacity were applied. Laboratory and radiographic examinations were performed. The aim of this study is to compare the clinical, epidemiological, genetic, imaging, treat- ment and prognosis characteristics of patients with enteropathic arthritis with other types of spondyloarthritis in a large Brazilian cohort. ResultsA total of 3.2% of patients were classified as having enteroarthritis, 2.5% had spon- dylitis and 0.7%, arthritis (peripheral predominance). The subgroup of individuals with en- teroarthritis had a higher prevalence in women (P < 0.001), lower incidence of inflammatory axial pain (P < 0.001) and enthesitis (P = 0.004). HLA-B27 was less frequent in the group with enteroarthritis (P = 0.001), even when considering only those with the pure axial form. There was a lower prevalence of radiographic sacroiliitis (P = 0.009) and lower radiographic score (BASRI) (P = 0.006) when compared to patients with other types of spondyloarthritis. They also used more corticosteroids (P < 0.001) and sulfasalazine (P < 0.001) and less non- steroidal anti-inflammatory drugs (P < 0.001) and methotrexate (P = 0.001). ConclusionThere were differences between patients with enteroarthritis and other types of spondyloarthritis, especially higher prevalence of females, lower frequency of HLA-B27, associated with less severe axial involvement.

Artrite enteropática no Brasil: dados do registro brasileiro de espondiloartrites

Inflammatory bowel diseases (Crohn's disease and ulcerative rectocolitis) have extraint- estinal manifestations 25% of the patients, with the most common one being the entero- pathic arthritis. MethodsProspective, observational, multicenter study with patients from 29 reference cen- ters participating in the Brazilian Registry of Spondyloarthritis (RBE), which incorporates the RESPONDIA (Ibero-American Registry of Spondyloarthritis) group. Demographic and clinical data were collected from 1472 patients and standardized questionnaires for the as- sessment of axial mobility, quality of life, enthesitic involvement, disease activity and func- tional capacity were applied. Laboratory and radiographic examinations were performed. The aim of this study is to compare the clinical, epidemiological, genetic, imaging, treat- ment and prognosis characteristics of patients with enteropathic arthritis with other types of spondyloarthritis in a large Brazilian cohort. ResultsA total of 3.2% of patients were classified as having enteroarthritis, 2.5% had spon- dylitis and 0.7%, arthritis (peripheral predominance). The subgroup of individuals with en- teroarthritis had a higher prevalence in women (P < 0.001), lower incidence of inflammatory axial pain (P < 0.001) and enthesitis (P = 0.004). HLA-B27 was less frequent in the group with enteroarthritis (P = 0.001), even when considering only those with the pure axial form. There was a lower prevalence of radiographic sacroiliitis (P = 0.009) and lower radiographic score (BASRI) (P = 0.006) when compared to patients with other types of spondyloarthritis. They also used more corticosteroids (P < 0.001) and sulfasalazine (P < 0.001) and less non-steroidal anti-inflammatory drugs (P < 0.001) and methotrexate (P = 0.001). ConclusionThere were differences between patients with enteroarthritis and other types of spondyloarthritis, especially higher prevalence of females, lower frequency of HLA-B27, associated with less severe axial involvement.